Vector VestAdvertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rhodey Red
Search This Board:
Last Post: 1/31/2015 3:58:29 AM - Followers: 309 - Board type: Free - Posts Today: 2

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.  Webcast from Cowen Healthcare Conference 03/03/14  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW 
Blog Update from CEO B. Culley 12/12/13  NEW  Data From Proof of Concept Study in Heart Failure 

2015 Biotech Conference Presentation Slides: January 12th 2015.

A service of the U.S. National Institutes of Health


  • Make bi


Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc. Identifier:
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
Further study details as provided by Mast Therapeutics, Inc.:
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline


Please refer to this study by its identifier: NCT01737814

Contact: Mast Therapeutics Call Center 1-888-965-1238  

Responsible Party: Mast Therapeutics, Inc. Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on July 25, 2013





MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.


2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing

Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14

2015 Event Schedule

Initiate dosing Phase2a study in AIR001 Q1 '15

Nonclinical Study EMBOLIC STROKE Data Q1 '15

Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15

EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15

Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15

Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15




Phase 2 Study Acute Limb Ischemia COMPLETE ENROLLMENT 2nd Half '16


Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug


Schedule 13D and 13G filings submitted since 09/30/14

  Filing Company Date of
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 03/31/14 3,000,000 3,000,000
SC 13G SABBY MANAGEMENT, LLC 1/21/15 11,605,388 11,605,388
SC 13G FRANKLIN RESOURCES INC 07/10/2013 10,987,000 12,000,000
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F MPM Asset Management     MSTX 2,551,851    
13F Vanguard Group     MSTX 2,810,791    




Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries

Investor Relations Contact

Business Development Contact

Careers Contact




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#12587   that is a strange first post...i added a hogfan2 01/31/15 03:58:29 AM
#12586   This is likely to hit the .30's soon. ErictheInvestor 01/31/15 12:13:42 AM
#12585   Important nugget from the CEO Blog...the nonclinical data Rhodey Red 01/30/15 08:30:42 PM
#12584   New CEO Blog posted today: Rhodey Red 01/30/15 04:31:19 PM
#12583   I've never understood the 'only invest what you Meeksie_t 01/30/15 02:16:56 AM
#12582   Looks like more diluting. No way folks selling pray 01/29/15 11:51:21 PM
#12581   Creative Planning just released their December 31, 2014 Rhodey Red 01/29/15 02:30:42 PM
#12580   In February mstx has 13F forms release showing Woulfe 01/29/15 12:30:38 PM
#12579   Not meaning to dig Rhodney out as I Meeksie_t 01/29/15 12:00:18 PM
#12578   Think the shorts just got back in. Culley pray 01/29/15 11:52:15 AM
#12577   No, you're right. Meeksie_t 01/29/15 11:43:44 AM
#12576   I'm just linking an article that refers to Rhodey Red 01/29/15 11:02:43 AM
#12575   Rhodney - Heard/seen that many many times before. Meeksie_t 01/29/15 10:01:53 AM
#12574   Jumped back in here for a longer term $TRIG$ 01/29/15 09:58:52 AM
#12573   Short interest Decrease!! Rhodey Red 01/29/15 08:19:46 AM
#12572   § MSTX Added at support here. § ipulator_man 01/28/15 04:33:33 PM
#12570   Well they will announce the new COO & Woulfe 01/28/15 12:47:45 PM
#12569   There goes Keran! Shakin' it up! ipulator_man 01/27/15 04:43:22 PM
#12568   Yes, in less then a year ppl will Woulfe 01/27/15 12:35:31 PM
#12567   This is what I firmly believe. This can Meeksie_t 01/27/15 04:14:38 AM
#12566   It will be interesting to see what happens JDLAXXE 01/27/15 12:39:29 AM
#12565   Can I get a little paint to back ipulator_man 01/26/15 07:11:37 PM
#12564   My thoughts exactly. Just hope Cully does not pray 01/26/15 02:36:46 PM
#12563   You may well be right, but why isn't Meeksie_t 01/26/15 04:54:48 AM
#12562   "The experience he's gained will no doubt serve ipulator_man 01/26/15 01:19:19 AM
#12560   Reposting this from 8/30/14 as a recap of Rhodey Red 01/25/15 09:51:32 PM
#12559   $MSTX...I'm still waiting to jump in...hog hogfan2 01/24/15 11:05:08 PM
#12558   Yes, wouldn't disagree with any of that. Meeksie_t 01/24/15 10:52:20 PM
#12557   I like the restructuring: New board member, New Rhodey Red 01/24/15 10:34:19 PM
#12556   It certainly raised an eyebrow or 2, but Meeksie_t 01/24/15 10:13:46 PM
#12555   Wow a Saturday night News release!!! I heard Rhodey Red 01/24/15 09:01:26 PM
#12554   The president/COO stepped down. No successor named yet. Woulfe 01/24/15 08:19:07 PM
#12553   Any thoughts why if "Sappy" bought over 11 pray 01/23/15 12:41:44 PM
#12552   You are 100% correct that EPIC data Q1'16 Rhodey Red 01/22/15 07:17:21 AM
#12551   Very good, Rhodders. Meeksie_t 01/21/15 08:25:09 PM
#12550   Sabby Management now owns 11,605,388 shares!!!! Not too S(h)abby!!! Rhodey Red 01/21/15 05:17:15 PM
#12549   Sabby Management just filed an amended 13G...they added Rhodey Red 01/21/15 04:34:40 PM
#12548   Sabby Hlthcare Mas. Fund and Vol Master Fund, laker2000 01/21/15 04:00:54 PM
#12547   Ya this volume is ridiculously low. No real Woulfe 01/21/15 01:51:47 PM
#12546   Not if the volume stays this low. From pray 01/21/15 01:09:32 PM
#12545   MSTX back into .40's! Buy the dip bebe! JDLAXXE 01/21/15 12:33:38 AM
#12544   More publicity is good publicity! Woulfe 01/20/15 02:25:53 PM
#12543   Haha! Meeksie_t 01/18/15 02:37:04 AM
#12542   Mast scheduled to present in February: Rhodey Red 01/17/15 10:09:15 PM
#12541   $MSTX...nothing wrong with the stock just ran up hogfan2 01/15/15 04:36:25 PM
#12540   Hit send on previous post by accident. Anyways, Woulfe 01/15/15 02:21:37 PM
#12539   On track with all trials, no debt; Woulfe 01/15/15 02:20:21 PM
#12538   Until the close in the green. Not really pray 01/14/15 11:00:09 PM
#12537   Your speculation is incorrect. I have never posted Meeksie_t 01/14/15 09:13:29 PM
#12536   Not sure if this is the case but pray 01/14/15 08:16:28 AM